DE602004024179D1 - Staphylococcus epidermidis antigene - Google Patents

Staphylococcus epidermidis antigene

Info

Publication number
DE602004024179D1
DE602004024179D1 DE602004024179T DE602004024179T DE602004024179D1 DE 602004024179 D1 DE602004024179 D1 DE 602004024179D1 DE 602004024179 T DE602004024179 T DE 602004024179T DE 602004024179 T DE602004024179 T DE 602004024179T DE 602004024179 D1 DE602004024179 D1 DE 602004024179D1
Authority
DE
Germany
Prior art keywords
antigene
staphylococcus epidermidis
antigens
hyperimmune serum
serum reactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004024179T
Other languages
English (en)
Inventor
Andreas Meinke
Bui Duc Min
Eszter Nagy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of DE602004024179D1 publication Critical patent/DE602004024179D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
DE602004024179T 2003-03-31 2004-03-31 Staphylococcus epidermidis antigene Expired - Lifetime DE602004024179D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03450078 2003-03-31
PCT/EP2004/003398 WO2004087746A2 (en) 2003-03-31 2004-03-31 Staphylococcus epidermidis antigens

Publications (1)

Publication Number Publication Date
DE602004024179D1 true DE602004024179D1 (de) 2009-12-31

Family

ID=33104246

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024179T Expired - Lifetime DE602004024179D1 (de) 2003-03-31 2004-03-31 Staphylococcus epidermidis antigene

Country Status (8)

Country Link
US (4) US7628994B2 (de)
EP (2) EP2182065A3 (de)
JP (1) JP2007523609A (de)
AT (1) ATE449177T1 (de)
AU (1) AU2004226262A1 (de)
CA (1) CA2520868A1 (de)
DE (1) DE602004024179D1 (de)
WO (1) WO2004087746A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523609A (ja) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト 表皮ブドウ球菌抗原
WO2005005630A2 (en) * 2003-07-08 2005-01-20 Umc Utrecht Holding B.V. Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases
EP1802335A2 (de) * 2004-10-21 2007-07-04 Wyeth a Corporation of the State of Delaware Immunogene zusammensetzungen aus staphylococcus-epidermidis-polypeptid- und polynukleotid-antigenen
EP1915396A2 (de) * 2005-06-13 2008-04-30 Nabi Biopharmaceuticals Verwendung von panton-valentin-leukocidin zur behandlung und prävention von staphylokokkeninfektionen
EP2117574A4 (de) 2007-01-24 2010-06-16 Merck Sharp & Dohme Polypeptide zur induzierung einer schützenden immunantwort gegen staphylococcus epidermidis
EP1980269A1 (de) * 2007-04-13 2008-10-15 Katholieke Universiteit Leuven Prävention von Staphylokokken-Biofilmbildung
RU2536981C9 (ru) 2009-06-22 2015-05-10 ВАЙЕТ ЭлЭлСи Иммуногенные композиции антигенов staphylococcus aureus
WO2013184900A2 (en) * 2012-06-06 2013-12-12 Sanofi Pasteur Biologics, Llc Immunogenic compositions and related methods
ITNA20120046A1 (it) * 2012-08-02 2014-02-03 No Self S R L Uso di acidi nucleici di sistemi biologici parassiti, patogeni e infestanti per l'inibizione e/o controllo degli stessi sistemi
NL2022581B1 (en) * 2019-02-14 2020-08-27 Koppert Bv Composition comprising a mixture of dna molecules, uses thereof as biological inhibitor and method for production

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DK0533838T3 (da) 1990-06-11 1998-02-23 Nexstar Pharmaceuticals Inc Nukleinsyreligander
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
WO1998008856A2 (de) 1996-08-30 1998-03-05 Fuerste Jens Peter Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US6958239B2 (en) 1996-11-21 2005-10-25 Oligos Etc Inc. Three component chimeric antisense oligonucleotides
US6380370B1 (en) * 1997-08-14 2002-04-30 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
ES2559317T3 (es) * 1999-10-29 2016-02-11 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria
WO2001034809A2 (en) * 1999-11-09 2001-05-17 Glaxo Group Limited Staphylococcus epidermidis nucleic acids and proteins
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AU2001267349A1 (en) 2000-04-14 2001-10-30 Cistem Biotechnologies Gmbh Pharmaceutical preparations comprising modified peptides
TR200302015T4 (tr) 2000-06-08 2004-01-21 Intercell Biomedizinische Forschungs-Und Entwicklungs Ag İmüno-uyarıcı oligodeoksinükleotitler
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
AU2001289813B2 (en) 2000-08-17 2005-07-28 Intercell Ag A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
JP4097178B2 (ja) * 2000-10-03 2008-06-11 株式会社グリーンペプタイド 腫瘍抗原
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
AU2002306849A1 (en) 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003011899A2 (en) * 2001-08-02 2003-02-13 University Of Sheffield Antigenic polypeptides
US7615616B2 (en) * 2002-09-13 2009-11-10 The Texas A&M University System Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby
JP2007523609A (ja) 2003-03-31 2007-08-23 インターツェル・アクチェンゲゼルシャフト 表皮ブドウ球菌抗原

Also Published As

Publication number Publication date
US20120269843A1 (en) 2012-10-25
EP1608756A2 (de) 2005-12-28
EP2182065A2 (de) 2010-05-05
ATE449177T1 (de) 2009-12-15
CA2520868A1 (en) 2004-10-14
US8372410B2 (en) 2013-02-12
US20130122030A1 (en) 2013-05-16
WO2004087746A3 (en) 2005-04-21
US8236325B2 (en) 2012-08-07
US7628994B2 (en) 2009-12-08
US20100297162A1 (en) 2010-11-25
US20070036778A1 (en) 2007-02-15
JP2007523609A (ja) 2007-08-23
AU2004226262A1 (en) 2004-10-14
EP2182065A3 (de) 2010-09-15
WO2004087746A2 (en) 2004-10-14
EP1608756B1 (de) 2009-11-18

Similar Documents

Publication Publication Date Title
ATE441715T1 (de) Streptococcus pyogenes antigene
WO2004092209A3 (en) S. pneumoniae antigens
WO2005103073A3 (en) Td antigens
WO2004099242A3 (en) Streptococcus agalactiae antigens i + ii
CY1114851T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων
ATE554107T1 (de) Als therapeutika geeignete monovalente antikörperfragmente
WO2002062850A3 (en) Hybrid antibodies and uses thereof
NO20054836L (no) Nogo-reseptorbindingsprotein
BRPI0411854A (pt) veìculos protéicos para vacinas
WO2004029072A3 (en) PrPsc -INTERACTING MOLECULES AND USES THEREOF
WO2004106367A3 (en) Enterococcus antigens
ATE449177T1 (de) Staphylococcus epidermidis antigene
WO2004094467A3 (en) H. pylori antigens
ATE477274T1 (de) Gegen clostridium difficile gerichtete antikörper
WO2004046314A3 (en) Methods for detecting asymmetric dimethylarginine in a biological sample
WO2001066752A3 (en) Reproduction-specific genes
CY1117395T1 (el) Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων

Legal Events

Date Code Title Description
8364 No opposition during term of opposition